Table of Contents

I. Heider et al.: Dopaminergic neurotoxicity of homocysteine and its derivatives in primary mesencephalic cultures.- D. Woitalla et al.: MTHFR C 677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson's disease.- A. S. Glass et al.: Screening for mutations in synaptotagmin XI in Parkinson's disease.- A. Heinz et al.: Depletion and restoration of endogenous monoamines affects ß-CIT binding to serotonin but not dopamine transporters in non-human primates.- J. Uekermann et al.: Differential executive control impairments in early Parkinson's disease.- S. Muhlack et al.: Simple movement sequences better correlate to levodopa plasma levels than complex ones.- Ch. Börnke et al.: Clinical effects of repetitive transcranial magnetic stimulation versus acute levodopa challenge in Parkinson's disease.- G. Schmid et al.: Impact of apomorphine on BOLD signal during movement in normals.- Th. Müller et al.: Worsened motor test performance following acute apomorphine injection in previously untreated patients with Parkinson's disease.- D. Woitalla et al.: Transdermal lisuride delivery in the treatment of Parkinson's disease.- C. Saft, C. et al.: Congruent deterioration of complex and simple movements in patients with Huntington's disease.- N. Brune et al.: Methyltetrahydrofolate reductase polymorphism influences onset of Huntington's disease.- J. Andrich et al.: Coenzyme Q10 serum levels in Huntington's Disease.- A. Beister et al.: The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease.- Th. Postert et al.: Transcranial sonography in spinocerebellar ataxia type 3.- L. Schöls et al.: Therapeutic strategies in Friedreich's ataxia.- V. G. Hösing et al.: Cholecystokinin- and cholecystokinin-B-receptor gene polymorphgisms in panic disorder